We surmise that our current findings may account for the mechanisms in drug efficacy of the Nrf2 inducer Tecfidera, which is used for the treatment of multiple sclerosis12, 13, because IL-6 and IL-1 are the key players in the development of multiple sclerosis and other autoimmune diseases. Here, IL1A is linked to autoimmune disease.